Product Data Sheet

SRPIN340



Cat. No.:	B2032
CAS No.:	218156-96-8
Formula:	C18H18F3N3O
M.Wt:	349.35
Synonyms:	
Target:	Microbiology & Virology
Pathway:	SRPK
Storage:	Store at -20°C

Solvent & Solubility

In Vitro

insoluble in H2O; ⩾10.9 mg/mL in DMSO; ⩾26.5 mg/mL in EtOH

Preparing Stock Solutions

Mass / Solvent / Concentration	1mg	5mg	10mg
1 mM	2.8625 mL	14.3123 mL	28.6246 mL
5 mM	0.5725 mL	2.8625 mL	5.7249 mL
10 mM	0.2862 mL	1.4312 mL	2.8625 mL

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Shortsummary	Selective SRPK1 inhibitor
IC_{50} & Target	0.89 μM(Ki) (SRPK1)

In Vitro

Cell Viability Assay

Cell Line:	A375, Omm2.5, Mel270 and 92.1 cells
Preparation method:	The solubility of this compound in DMSO is >10.9mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37°C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.
Reacting conditions:	10 μM; 24 hours

	Applications:	In A375 cells, SRPIN340 resulted in a 54% reduction in the IGF-1 induced nuclear localisation of SRSF1. In Mel270 cells, SRPIN340 significantly reduced the proportion of nuclear SRSF1 compared with IGF-1 treatment alone. In A375, Omm2.5 and 92.1 cells, SRPIN340 reduced total VEGF protein.
In Vivo	**Animal experiment**	
	Animal models:	Mice bearing A375-untransfected tumours
	Dosage form:	100 µl of 20 µg/ml SRPIN340 (diluted 100× in PBS from 2mg/ml stock in DMSO); injected daily into the peritumoral space
	Applications:	In mice bearing A375-untransfected tumours, SRPIN340 significantly reduced tumour growth compared with DMSO control-injected tumours. SRPIN340 also reduced total VEGF expression and significantly reduced microvascular density (MVD).
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

Product Citations

See more customer validations on www.apexbt.com.

References

[1]. M V Gammons, R Lucas, R Dean, et al. Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma. Br J Cancer. 2014 Jul 29; 111(3): 477-485.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com